• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Propeller wins FDA nod for connected GSK Ellipta inhaler

November 7, 2016 By Sarah Faulkner

Propeller wins FDA nod for connected GSK Ellipta inhalerPropeller Health said today that it won 510(k) clearance from the FDA to market its Propeller platform with GlaxoSmithKline‘s (NYSE:GSK) Ellipta inhaler. A sensor for the dry powder inhaler was built as a part of a 1 year-long development and R&D collaboration between Propeller and GSK.

This marks the 8th clearance for Propeller’s connected inhaler platform.

The Madison, Wisconsin-based company won CE Mark approval and Health Canada registration for the use of its connected platform with the Ellipta inhaler earlier this year.

Propeller’s sensor technology and software is designed to be used by patients and physicians to keep track of symptoms and outcomes for chronic respiratory diseases such as asthma and COPD. The platform can integrate data from multiple sources, like connected devices, and uses machine learning to help patients manage their condition, according to Propeller.

“Today, we are pleased to announce the FDA clearance of the Propeller platform for use with GSK’s Ellipta inhaler,” co-founder & CEO David Van Sickle said in prepared remarks. “Inclusion of GSK’s Ellipta inhaler in Propeller’s digitally-guided therapy platform is an important step in our goal of modernizing the management of respiratory disease. We look forward to working closely with GSK to deploy sensors for the Ellipta inhaler in the U.S. and abroad, in the near term.”

“While it is still in the early stages of development, the emerging field of digital healthcare holds great promise for respiratory medicine,” GSK respiratory R&D head Dave Allen added. “The approval of the Propeller platform for use with the Ellipta inhaler will help us understand how patients interact with the Ellipta inhaler accurately and in real-time. By exploring the benefits of sensor technology in this way, we hope to gain valuable insights into usage patterns with the ultimate goal of driving improvements in patient care while reducing the complexity and cost of clinical trials.”

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), mHealth (Mobile Health), Respiratory Tagged With: GlaxoSmithKline plc, Propeller Health

IN CASE YOU MISSED IT

  • BD files patent infringement lawsuit against Baxter over infusion pump tech
  • Tandem Diabetes Care subsidiary earns new FDA clearance for insulin infusion set
  • Glucotrack can proceed with long-term glucose monitor study in Australia
  • Dexcom promotes Jake Leach to president role
  • Roche invests $550M to make Indianapolis a CGM manufacturing hub

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS